Citigroup Maintains Buy on Larimar Therapeutics, Raises Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Samantha Semenkow maintains a Buy rating on Larimar Therapeutics (NASDAQ:LRMR) and raises the price target from $10 to $14.
May 22, 2024 | 5:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citigroup analyst Samantha Semenkow maintains a Buy rating on Larimar Therapeutics and raises the price target from $10 to $14.
The raised price target and maintained Buy rating from a reputable analyst at Citigroup is likely to positively impact investor sentiment and drive short-term price appreciation for Larimar Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100